Mark Rosen

11.2k total citations · 1 hit paper
178 papers, 7.8k citations indexed

About

Mark Rosen is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Mark Rosen has authored 178 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Radiology, Nuclear Medicine and Imaging, 43 papers in Pulmonary and Respiratory Medicine and 26 papers in Oncology. Recurrent topics in Mark Rosen's work include MRI in cancer diagnosis (54 papers), Radiomics and Machine Learning in Medical Imaging (42 papers) and Advanced MRI Techniques and Applications (29 papers). Mark Rosen is often cited by papers focused on MRI in cancer diagnosis (54 papers), Radiomics and Machine Learning in Medical Imaging (42 papers) and Advanced MRI Techniques and Applications (29 papers). Mark Rosen collaborates with scholars based in United States, United Kingdom and India. Mark Rosen's co-authors include Mitchell D. Schnall, Peter J. O’Dwyer, Anant Madabhushi, Carolyn Mies, Michael D. Feldman, Gerald R. Cunha, Simon W. Hayward, Arjun G. Yodh, Regine Choe and Turgut Durduran and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and PLoS ONE.

In The Last Decade

Mark Rosen

176 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials

2018 252 citations Thomas L. Chenevert, Dariya Malyarenko et al. Journal of Magnetic Resonance Imaging profile →

Peers

Countries citing papers authored by Mark Rosen

Since Specialization

Citations

This map shows the geographic impact of Mark Rosen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rosen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rosen more than expected).

Fields of papers citing papers by Mark Rosen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rosen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rosen. The network helps show where Mark Rosen may publish in the future.

Co-authorship network of co-authors of Mark Rosen

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Rosen. A scholar is included among the top collaborators of Mark Rosen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Rosen. Mark Rosen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study 2024 ·Immuno-Oncology Technology ·Antoine Italiano, (unknown), Hossein Borghaei, Sanjay Popat, Geòrgia Anguera, Anthony Gonçalvès, (unknown), Julien Mazières, (unknown), (unknown), (unknown), Antonio Calles, David Vicente Baz, Michael Chisamore, Daniel Barrios, Kazuhiro Abe, Dipica Haribhai, Mark Rosen, Bruce L. Cunningham, Luis Paz‐Ares	3
2	Myofibroblastoma in the Liver: A Case Report and Review of Literature 2023 ·International Journal of Surgical Pathology ·Mohan Narasimhamurthy, (unknown), Lauren Shreve, Mark Rosen, (unknown), Kumarasen Cooper, Emma E. Furth, Paul J. Zhang, Zhaohai Yang	0
3	Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma 2023 ·Journal of Clinical Oncology ·William A. Hall, Jiahe Li, Y. Nancy You, Marc J. Gollub, Joseph R. Grajo, Mark Rosen, (unknown), Greg Yothers, Jennifer A. Dorth, Osama E. Rahma, Marcia M. Russell, Howard M. Gross, Samuel A. Jacobs, Bryan A. Faller, (unknown), Tareq Al Baghdadi, Michael G. Haddock, Richard K. Valicenti, Theodore S. Hong, Thomas J. George	15
4	Quality Improvement Report: Design and Implementation of a Radiology E-Consult Service 2023 ·Radiographics ·(unknown), (unknown), Charles E. Kahn, Mitchell D. Schnall, Mark Rosen, Hanna M. Zafar, Scott O. Trerotola, Tessa S. Cook	2
5	Impact of Arterial Input Function and Pharmacokinetic Models on DCE-MRI Biomarkers for Detection of Vascular Effect Induced by Stroma-Directed Drug in an Orthotopic Mouse Model of Pancreatic Cancer 2023 ·Molecular Imaging and Biology ·Jianbo Cao, Stephen Pickup, Mark Rosen, Rong Zhou	2
6	DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models 2022 ·Cancers ·(unknown), Emma E. Furth, Yong Fan, (unknown), Stephen Pickup, Jianbo Cao, Hoon Choi, (unknown), Quy Cao, Russell T. Shinohara, Deirdre McMenamin, Cynthia Clendenin, Thomas B. Karasic, Jeffrey Duda, James C. Gee, Peter J. O’Dwyer, Mark Rosen, Rong Zhou	7
7	Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial 2022 ·Tomography ·Savannah C. Partridge, Jon A. Steingrimsson, David C. Newitt, Jessica Gibbs, Helga S. Marques, Patrick J. Bolan, Michael A. Boss, Thomas L. Chenevert, Mark Rosen, Nola M. Hylton	7
8	Repeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG‐ACRIN Research Group (ACRIN 6701) 2022 ·Journal of Magnetic Resonance Imaging ·Michael A. Boss, Bradley S. Snyder, Eun‐Hee Kim, (unknown), Sarah Englander, Karthik M. Sundaram, Naveen Gumpeni, Suzanne L. Palmer, Haesun Choi, Adam T. Froemming, Thorsten Persigehl, Matthew S. Davenport, Dariya Malyarenko, Thomas L. Chenevert, Mark Rosen	12
9	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank 2021 ·Journal of the American Medical Informatics Association ·Matthew T. MacLean, Qasim Jehangir, Marijana Vujković, Yi-An Ko, Harold Litt, Arijitt Borthakur, Hersh Sagreiya, Mark Rosen, David A. Mankoff, Mitchell D. Schnall, Haochang Shou, Julio A. Chirinos, Scott M. Damrauer, Drew A. Torigian, Rotonya M. Carr, Daniel J. Rader, Walter R. Witschey	14
10	Adaptive convolutional neural networks for accelerating magnetic resonance imaging via k-space data interpolation 2021 ·Medical Image Analysis ·Tianming Du, Honggang Zhang, Yuemeng Li, Stephen Pickup, Mark Rosen, Zhou Rong, Hee Kwon Song, Yong Fan	27
11	Respiratory Motion Mitigation and Repeatability of Two Diffusion-Weighted MRI Methods Applied to a Murine Model of Spontaneous Pancreatic Cancer 2021 ·Tomography ·Jianbo Cao, Hee Kwon Song, (unknown), (unknown), Jinbo Chen, Cynthia Clendenin, Mark Rosen, Rong Zhou, Stephen Pickup	3
12	Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients 2021 ·Liver Transplantation ·(unknown), (unknown), (unknown), (unknown), David D. Aufhauser, (unknown), Evan S. Siegelman, Mark Rosen, K. Rajender Reddy, Maarouf Hoteit, Emma E. Furth, Kim M. Olthoff, Abraham Shaked, Matthew H. Levine, Peter L. Abt	5
13	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer 2019 ·Clinical Cancer Research ·Amy S. Clark, Nicholas P. McAndrew, Andrea B. Troxel, Michael D. Feldman, Priti Lal, Mark Rosen, (unknown), Colleen Redlinger, Maryann Gallagher, Angela R. Bradbury, Susan M. Domchek, Kevin R. Fox, Peter J. O’Dwyer, Angela DeMichele	35
14	Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma 2018 ·Clinical Cancer Research ·Jianbo Cao, Stephen Pickup, Cynthia Clendenin, Barbara Blouw, Hoon Choi, David W. Kang, Mark Rosen, Peter J. O’Dwyer, Rong Zhou	23
15	CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment 2014 ·Clinical Cancer Research ·Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael D. Feldman, Paul J. Zhang, Christopher Colameco, David A. Lewis, Melissa Langer, Noah Goodman, Susan M. Domchek, Keerthi Gogineni, Mark Rosen, Kevin R. Fox, Peter J. O’Dwyer	280
16	Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL 2012 ·Radiology ·Nola M. Hylton, Jeffrey D. Blume, Wanda K. Bernreuter, Etta D. Pisano, Mark Rosen, Elizabeth A. Morris, Paul T. Weatherall, Constance D. Lehman, Gillian M. Newstead, (unknown), Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall	359
17	Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation 2011 ·Clinical Cancer Research ·Danny Rischin, David C. Bibby, Geoff Chong, Gabriel Kremmidiotis, Annabell F. Leske, (unknown), Shirley Wong, Mark Rosen, Jayesh Desai	54
18	A Pragmatic Approach for Sustainable Development of the Red-Mediterranean-Dead Seas Canal Project: A Case Study 2011 ·International Journal of Ecology & Development ·Mark Rosen, (unknown)	8
19	Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: A case study with comparison to MRI 2005 ·Medical Physics ·Regine Choe, Alper Corlu, Kijoon Lee, Turgut Durduran, Soren D. Konecky, (unknown), Simon Arridge, Brian J. Czerniecki, Douglas L. Fraker, Angela DeMichele, Britton Chance, Mark Rosen, Arjun G. Yodh	228
20	CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. 2003 ·PubMed ·Christopher J. Strock, Jong‐In Park, Mark Rosen, Craig A. Dionne, Bruce Ruggeri, Susan Jones‐Bolin, Samuel R. Denmeade, Douglas W. Ball, Barry D. Nelkin	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact